Researcher Profile
Holcombe E. Grier, MD
Professor of Pediatrics, Harvard Medical School
Center/Program
Department
Area of Research
Pediatric Sarcomas
Contact Information
Holcombe E. Grier, MDDana-Farber Cancer Institute
44 Binney Street
Dana G350
Boston, MA 02115
Office phone: (617) 632-3971
Fax: (617) 632-5710
E-mail: holcombe_grier@dfci.harvard.edu
Preferred contact method: office phone
Research
At the Children's Oncology Group, we work on the design and implementation of studies regarding Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas. The Children's Oncology Group is a consortium of cancer treatment centers across the United States, Canada, and other countries. Dr. Grier is an active member of the Bone Tumor Disease Committee and the Soft Tissue Sarcoma Committee of this group.
As part of the Pediatric Solid Tumor group at DFCI and Children's Hospital, we help organize laboratory and clinical cross talk.
We are also involved in cancer survivor studies that focus on the late effects of chemotherapy. These studies are led by Dr. Lisa Diller at the David B. Perini Jr. Quality of Life Clinic at DFCI. In addition, we participate in a study of the best application of palliative care through our work with the Pediatric Advanced Care Team, led by Dr. Joanne Wolfe.
Recent Awards
- Ray A. Kroc Visiting Professor of Pediatrics, The Hospital for Sick Children and McMaster University, Toronto and Hamilton, Canada, 1999
- Charles A. Janeway Award for Excellence in Clinical Teaching, Children's Hospital House Staff, Boston, 1992
Biography
Dr. Grier received his MD from the University of Pennsylvania in 1976, and then trained in pediatrics, internal medicine, and infectious disease at the University of North Carolina. He joined Dana-Farber Cancer Institute in 1984. He is currently on the executive committee of the Children's Oncology Group, and is a trustee for the American Society of Pediatric Hematology/Oncology.
Select Publications
- Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005:2004-11.
- Pappo AS, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, Gebhardt M, Pratt C, Grier HE. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 2005;23:4031-8.
- Mack JW, Grier HE. The day one talk. J Clin Oncol 2004;22:563-6.
- Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Grier HE. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide - a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004;22:2873-6.
- Viswanathan AN, Grier HE, Litman HJ, Perez-Atayde A, Tarbell NJ, Neuberg D, Shamberger RC, Marcus KJ. Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:1208-14.
- Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
Clin Cancer Res 2003;9:5442-53. - Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
- Marcus KJ, Shamberger R, Litman H, von Allmen D, Grupp SA, Nancarrow CM, Goldwein J, Grier HE, Diller L. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol 2003;25:934-40.
- Rahbar R, Vargas SO, Miyamoto CR, Perez-Atayde AR, French CA, Robson CD, Licameli GR, Fletcher JA, Marcus KC, Grier HE, McGill TJ, Healy GB. The role of chromosomal translocation (15;19) in the carcinoma of the upper aerodigestive tract in children. Otolaryngol Head Neck Surg 2003;129:698-704.
- Shamberger RC, LaQuaglia MP, Gebhardt MC, Neff JR, Tarbell NJ, Marcus KC, Sailer SL, Womer RB, Miser JS, Dickman PS, Perlman EJ, Devidas M, Linda SB, Krailo MD, Grier HE, Granowetter L. Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 2003;238:563-7.
